ZYUS Life Sciences Corporation Announces Closing of Second Tranche of Secured Loan Financing and Provides an Update on its Annual Filings and Q1 2026 Financial Statement

The most recent news (May 28, 2026) reports the closing of a second CAD$265,000 tranche of a secured loan, bringing total gross proceeds under that facility to only CAD$445,000 out of a potential CAD$2 million. The loan carries 12 % interest, matures November 19, 2026, and is secured by a general security agreement. One insider participated (CAD$45,000). More critically, the Company disclosed that both its Q1 2026 interim financial statements and its annual 2025 audited financials remain delayed due to complex accounting matters—specifically asset valuation—with external auditors KPMG. A failure‑to‑file cease trade order (FFCTO) imposed by the Ontario Securities Commission on May 6, 2026, remains in effect until those annual filings are completed. No new filing timeline was given.

The May 28 update must be read in the context of a steadily deteriorating financial and regulatory picture. The company has been scrambling for small, high‑cost debt since at least mid‑2025. A planned C$15 – 16 million “LIFE” offering was cancelled outright (Feb 24, 2026); a subsequent non‑brokered private placement of up to C$7 million appears not to have closed, forcing ZYUS to rely on piece‑meal secured loans from its CEO and an independent director. Total known insider‑linked loan facilities now exceed C$2.7 million (some matured/extended), and each new loan includes sweeteners (warrants, high interest) that dilute the recovery prospects for common shareholders. The latest CAD$445,000 is insufficient to fund ongoing clinical trials or general working capital for more than a few weeks—the company is effectively standing still.

The real material blow is the open‑ended audit impasse and the FFCTO. When the delay was first announced on April 30, management expected to file by the week of May 18. That target was missed; on May 20 they projected the week of May 31. Now no date is offered, and the cease trade order bites. In Canada, an FFCTO prohibits trading in the company’s securities, essentially freezing any ability to raise new equity or even maintain a normal market. The “complex accounting matters” related to physical asset valuation—likely inventory or property, plant and equipment—raise the spectre of a material write‑down that could impair the balance sheet and possibly trigger a going‑concern warning. For a pre‑revenue biotech, losing the trust of its auditor and regulator is a red flag that dwarfs any pipeline progress.

Earlier positives—such as the second U.S. patent (May 5, 2026) and the Phase 2a last‑patient‑last‑visit milestone (April 16)—are now overshadowed. The market has already priced in severe distress: the stock fell from $0.58 on April 16 to $0.40 on May 4 when the CTO was being telegraphed, and has barely recovered to $0.50 despite the patent announcement. The cumulative news confirms that ZYUS has lost access to public capital markets, is burning through insider‑sourced cash, and faces a genuine existential threat if the audit cannot be resolved promptly and without a significant asset impairment.

ZYUS Life Sciences is a Canadian clinical‑stage company developing non‑opioid pain therapies. Its lead candidate, Trichomylin® softgel capsules, is a cannabinoid‑based formulation that completed Phase 1 and is now in a single‑arm Phase 2a proof‑of‑concept trial (UTOPIA‑1) for moderate‑to‑severe cancer‑related pain. The trial has three active Canadian sites and has enrolled at least 25 % of the target population; the last patient last visit occurred in April 2026, with top‑line results expected in Q2 2026. A second drug candidate, targeting neuropathic pain, is supported by U.S. Patent No. 12,616,704 (issued May 2026) and has completed IND‑enabling studies. The company has two U.S. patents and is pursuing regulatory exclusivity.